Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sorafenib Tosylate

FDA-approved product (tablet, oral), marketed as Nexavar, Sorafenib Tosylate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Sorafenib Tosylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chromophobe renal cell carcinoma
  • Clear cell renal carcinoma
  • Hepatocellular carcinoma
  • Papillary renal cell carcinoma
  • Papillary thyroid carcinoma
  • Renal cell carcinoma
  • Thyroid cancer
  • Thyroid carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli27.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sorafenib Tosylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.1 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sorafenib Tosylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • 17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors

    NCT00121264 · start 2005-03

    Registered record
    Registry ID
    NCT00121264
    Conditions
    Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    sorafenib tosylate; tanespimycin; laboratory biomarker analysis; pharmacological study; magnetic resonance imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-03
    Completion
    2010-07
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUnspecified Adult Solid Tumor, Protocol Specific
    Interventionsorafenib tosylate; tanespimycin; laboratory biomarker analysis; pharmacological study +1 more
    PhasePhase 1
    Registry statusCompleted

  • Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma

    NCT00093613 · start 2004-12

    Registered record
    Registry ID
    NCT00093613
    Conditions
    Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Gliosarcoma; Recurrent Adult Brain Tumor
    Interventions
    sorafenib tosylate; pharmacological study
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-12
    Completion
    2011-12
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Gliosarcoma +1 more
    Interventionsorafenib tosylate; pharmacological study
    PhasePhase 1
    Registry statusCompleted

  • BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer

    NCT00098254 · start 2004-12

    Registered record
    Registry ID
    NCT00098254
    Conditions
    Non-Small-Cell Lung Carcinoma
    Interventions
    BAY 43-9006 (Sorafenib)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-12
    Completion
    2011-01
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small-Cell Lung Carcinoma
    InterventionBAY 43-9006 (Sorafenib)
    PhasePhase 2
    Registry statusCompleted

  • Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer

    NCT00114244 · start 2004-12

    Registered record
    Registry ID
    NCT00114244
    Conditions
    Stage IV Pancreatic Cancer
    Interventions
    sorafenib tosylate; gemcitabine hydrochloride; laboratory biomarker analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-12
    Completion
    2010-09
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStage IV Pancreatic Cancer
    Interventionsorafenib tosylate; gemcitabine hydrochloride; laboratory biomarker analysis
    PhasePhase 2
    Registry statusCompleted

  • Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

    NCT00096200 · start 2004-08

    Registered record
    Registry ID
    NCT00096200
    Conditions
    Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
    Interventions
    Carboplatin; Paclitaxel; Sorafenib Tosylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-08
    Completion
    2011-08
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
    InterventionCarboplatin; Paclitaxel; Sorafenib Tosylate
    PhasePhase 2
    Registry statusCompleted